Management strategies for PMS/PMDD

Journal of Family Practice

Volumn 53, Issue SUPPL. 5, 2004, Pages

  Yonkers, Kimberly A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; CONJUGATED ESTROGEN; DESIPRAMINE; ETHINYLESTRADIOL; FLUOXETINE; FLUVOXAMINE; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; TRICYCLIC ANTIDEPRESSANT AGENT; GONADORELIN;

CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; PRACTICE GUIDELINE; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PREVALENCE; REVIEW; SYMPTOM; CONTROLLED CLINICAL TRIAL; DRUG POTENTIATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

CONTRACEPTIVES, ORAL; FEMALE; FLUOXETINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; PREMENSTRUAL SYNDROME; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 4544254124     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. International Statistical Classification of Diseases and Related Health Problems, 1989 revision. Geneva: World Health Organization; 1992.
2. Davis AJ, Johnson SR. Premenstrual syndrome. American College of Obstetricians and Gynecologists Practice Bulletin, No. 15. Washington, DC: American College of Obstetricians and Gynecologists; 2000.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
4. Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med. 2003;48:515-524.
5. Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry. 1997;58(suppl):4-10; discussion 11-13.
6. Freeman EW, Halbreich U. Premenstrual syndromes. Psychopharmacol Bull. 1998;34:291-295.
7. Tucker JS, Whalen RE. Premenstrual syndrome. Int J Psychiatry Med. 1991;21:311-341.
8. Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disotder (PMDD). Paper presented at: Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif.
9. Halbteich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase serttaline treatment of premenstrual dysphoric disotder. Obstet Gynecol. 2002;100:1219-1229.
10. Griffin L, Mellon S. Selective setotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci. 1999;96:13512-13517.
11. Freeman EW, Rickels K, Sondheimet SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry. 1999;56:932-939.
12. Steiner M, Steinberg S, Stewart D, et al, for the Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med. 1995;332:1529-1534.
13. Dimmock PW, Wyatt KM, Jones PW, Shaughn O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356:1131-1136.
14. Veeninga AT, Westenberg HG, Weusten JT. Fluvoxamine in the treatment of menstrually related mood disorders. Psychopharmacology (Berlin). 1990;102:414-416.
15. Muse KN, Cetel NS, Futterman LA, Yen SC. The premenstrual syndrome: effects of "medical ovariectomy." N Engl J Med. 1984;311:1345-1349.
16. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonisr and esrrogen/progestin. J Clin Endocrinol Metab. 1991;72:252A-252F.
17. Burnet RB, Radden HS, Easterbrook EG, McKinnon RA. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol. 1991;31:366-368.
18. O'Brien PM, Craven D, Selby C, Symonds EM. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol. 1979;86:142-147.
19. Vellacott ID, Shroff NE, Pearce MY, Srratford ME, Akbar FA. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin. 1987;10:450-456.
20. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand. 1995;74:803-808.
21. Wyatr K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ. 2001;323:776-780.
22. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology. 1993;18:273-281.
23. Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J Reprod Med. 2002;47:14-22.
24. Borenstein J, Yu H-T, Wade S, Chiou C-F, Rapkin A. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med. 2003;48:79-85.
25. Freeman EW, Kroll R, Rapkin A, et al, for the PMS/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001;10:561-569.